231 related articles for article (PubMed ID: 27658904)
1. Outcome and surgical strategy in critical sites in cases of psuedomyxoma peritonei.
Mahmoud AM; Hussein MM; Moneer MM
J Egypt Natl Canc Inst; 2016 Dec; 28(4):249-255. PubMed ID: 27658904
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
Lei ZY; Ding BH; Wu QY; Luo JL; Li Z; Wang T; Wang YS; Chen YX; Huang LF; He JF; Yang XS; Guan TP; Ruan Q; Wang JH; Tang HS; Wang J; Cui SZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1179-1186. PubMed ID: 38110280
[No Abstract] [Full Text] [Related]
4. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
5. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
[No Abstract] [Full Text] [Related]
6. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
[TBL] [Abstract][Full Text] [Related]
7. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
Tan GH; Novo CA; Dayal S; Chandrakumaran K; Mohamed F; Cecil T; Moran BJ
Eur J Surg Oncol; 2017 Feb; 43(2):388-394. PubMed ID: 27866811
[TBL] [Abstract][Full Text] [Related]
8. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms.
Narasimhan V; Pham T; Warrier S; Craig Lynch A; Michael M; Tie J; Ramsay R; Heriot A
ANZ J Surg; 2019 Sep; 89(9):1035-1040. PubMed ID: 30685879
[TBL] [Abstract][Full Text] [Related]
9. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
10. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China.
Wang B; Ma R; Shi G; Fan X; Rao B; Xu H
Orphanet J Rare Dis; 2024 Jan; 19(1):8. PubMed ID: 38178189
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
[TBL] [Abstract][Full Text] [Related]
14. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
[TBL] [Abstract][Full Text] [Related]
15. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
16. Clinical findings of patients with pseudomyxoma peritonei of appendiceal origin undergoing Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Iavazzo C; Spiliotis J
Updates Surg; 2020 Sep; 72(3):923-924. PubMed ID: 32602012
[No Abstract] [Full Text] [Related]
17. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report.
Thorgersen EB; Melum E; Folseraas T; Larsen SG; Line PD
World J Surg Oncol; 2018 Sep; 16(1):180. PubMed ID: 30185175
[TBL] [Abstract][Full Text] [Related]
18. Comparison of serial debulking and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei of appendiceal origin.
Järvinen P; Ristimäki A; Kantonen J; Aronen M; Huuhtanen R; Järvinen H; Lepistö A
Int J Colorectal Dis; 2014 Aug; 29(8):999-1007. PubMed ID: 24965858
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.
van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ
BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454
[TBL] [Abstract][Full Text] [Related]
20. The pre-operative neutrophil-lymphocyte ratio predicts overall and disease-free survival following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with pseudomxyoma peritonei of appendiceal origin.
Rangarajan K; Chandrakumaran K; Dayal S; Mohamed F; Moran BJ; Cecil TD
Int J Hyperthermia; 2018 Aug; 34(5):559-563. PubMed ID: 29063804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]